Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025. The company's CEO, Dr. Shawn Leland, will engage in a fireside chat on Tuesday, March 11, 2025, at 2:20 p.m. EDT.

Investors and interested parties can access a live webcast of the presentation through Affimed's website investor section. The presentation recording will remain available for 30 days following the event. For those interested in one-on-one meetings with Affimed's management team, arrangements can be made through Leerink Partners representatives or by contacting Alex Fudukidis.

News Market Reaction

-3.16%

1 alert

-3.16% News Effect

On the day this news was published, AFMD declined 3.16%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 at 2:20 p.m. Eastern Daylight Time.

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed’s management, please contact your Leerink Partners representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE^®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE^® are generated on the Company’s proprietary ROCK^® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE^® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When is Affimed (AFMD) presenting at the Leerink Partners Healthcare Conference 2025?

Affimed will present on Tuesday, March 11, 2025 at 2:20 p.m. Eastern Daylight Time.

How can investors watch Affimed's (AFMD) presentation at the Leerink Conference?

Investors can watch the live webcast through Affimed's website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/.

How long will Affimed's (AFMD) Leerink Conference presentation replay be available?

The presentation replay will be archived on Affimed's website for 30 days after the event.

How can investors schedule one-on-one meetings with Affimed's (AFMD) management at the Leerink Conference?

Investors can schedule meetings through their Leerink Partners representative or by contacting Alex Fudukidis at a.fudukidis@affimed.com or +1 (917) 436-8102.